Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma

Ren Ji, MD, FACS, Kelvin K. Ng, MS, PhD, FACS, FRCSEd (Gen), Weneric Chen, PhD, Weihong Yang, PhD, Hongtao Zhu, MD, Tan-To Cheung, MS, MD, PhD, FACS, FRCSEd (Gen), Chi-Leung Chiang, FCRP, Tiffany C.L. Wong, FACS, FRCSEd (Gen), Feng-Ming Kong, MD, PhD, FACR, FAAAA, FASTRO, Ren Ji, MD, FACSa, Kelvin K. Ng, Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong-Shenzhen Hospital, China, Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, China, Department of Interventional Radiology, Department of Medical Imaging, The University of Hong Kong-Shenzhen Hospital, China, Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Abstract
Stereotactic body radiotherapy (SBRT) is a novel noninvasive treatment for unresectable hepatocellular carcinoma (HCC). Whether its efficacy is comparable to radiofrequency ablation (RFA), a recommended therapy for unresectable HCC, is unknown. The present study aims to compare the clinical outcome between SBRT and RFA for patients with unresectable HCC.

The clinical data of 60 patients with unresectable HCC from January 2018 to January 2021 were retrospectively reviewed. There were 22 cases treated by SBRT and 38 cases by RFA. The short-term and long-term clinical outcomes were compared. There was no significant difference in the baseline demographic characteristics between two groups. The complete remission rate at 3 months was comparable between SBRT group (81.8%) and RFA group (94.7%). Local tumor control rate was also similar between two groups (90.9% vs. 94.7%). There was no severe complication (grade IIIa or above) in both groups. The 1-year and 2-year overall survival rates were 88.2% and 85.7% in SBRT group and 100% and 75% in RFA group, respectively. There was no statistical significant difference between groups ($P = .576$).

SBRT can achieve similar short and long-term clinical outcome as RFA for unresectable HCC. Future prospective clinical study is needed to justify its role in patients with HCC.

Abbreviations: AFP = alpha fetoprotein, CR = complete remission, CT = computer tomography, HCC = hepatocellular carcinoma, MRI = magnetic resonance imaging, RFA = radiofrequency ablation, SBRT = stereotactic body radiotherapy.

Keywords: body, carcinoma, hepatocellular, radiotherapy, stereotactic

1. Introduction

Hepatocellular carcinoma (HCC) is currently the sixth most common malignant tumor and the third leading cause of cancer death in the world in 2020.$[1,2]$ Hepatic resection offers the best treatment option for HCC with favorable 5-year overall survival rate up to 60%.$[2,3]$ However, the resectability rate patients with HCC remains low (about 20%) because of multicentric nature of tumor, unsatisfactory liver function, and propensity vascular invasion to portal venous system by tumor. Local ablation therapy using radiofrequency ablation (RFA) offers another viable treatment option for unresectable HCC.$[4,5]$ Even after curative hepatic resection, intrahepatic tumor recurrence is common (up to 50%–70%) because of intrahepatic metastasis through portal venous system and de novo tumor from the underlying hepatitis viral infection.$[6]$ It will then be preferable that local ablation therapy can be applied to these recurrent tumor if feasible.

The application of RFA for liver tumor is limited by difficult locations of tumors (dome of liver, subcapsular region in close proximity to internal organs and perivascular location), which will preclude the route of percutaneous approach for insertion of RFA needle. In other words, either laparoscopic or open approach is needed in those situations, which carry significant surgical trauma. Recently, stereotactic body radiotherapy (SBRT)
has evolved as a new local ablation therapy for HCC, which is totally noninvasive. It is external beam radiation therapy which is delivered in hypofractionated manner with high energy dose in each fraction by the use of advanced radiation planning and delivery. Early phase clinical trials of SBRT has proven its efficacy for HCC, with local tumor control rate up to 99% at follow-up period up to 3 years. Over the years, there has been limited retrospective studies in the literature comparing SBRT and RFA regarding the clinical efficacy for unresectable HCC. The reported short-term and mid-term outcome of SBRT were comparable to RFA. Moreover, SBRT has been shown to be effective for large HCC (>3 cm) at difficult anatomical location. Lately, meta-analysis studies even showed that SBRT had better local tumor control than RFA, although long-term overall survival results of SBRT was conflicting. To solidify the treatment role of SBRT for HCC, a retrospective comparative study was conducted in authors’ center. The present study aims to compare the clinical outcome between SBRT and RFA for patients with unresectable HCC, in terms of perioperative outcome, local tumor control, and long-term survival.

2. Patients and methods

This study has been approved by institutional review board of The University of Hong Kong-Shenzhen Hospital.

From January 2018 to January 2021, there were 60 patients with unresectable HCC who were treated by SBRT (n=22) or RFA (n=38) in the Department of Surgery, The University of Hong Kong-Shenzhen Hospital. The inclusion criteria for SBRT or RFA was as follows:

(a) The diagnosis of HCC followed the criteria used by the European Association for the Study of the Liver. HCC was diagnosed when the radiologic imaging techniques (spiral contrasted computer tomography [CT] scan or contrasted magnetic resonance imaging [MRI]) showed typical features of HCC (contrast enhancement in the arterial phase and rapid wash-out of contrast in the venous or delayed phase) and/or the serum alpha fetoprotein (AFP) level was elevated (>400 ng/mL).

(b) Unresectable HCC is due to poor liver function (Child-Pugh grade B or indocyanine green retention test >20% at 15 min in case of major hepatectomy).

(c) Tumor size ≤ 5 cm and/or no. of tumors ≤ 3.

(d) Absence of portal vein invasion.

(e) Absence of extrahepatic metastasis.

(f) Liver function status of Child-Pugh grade A or B.

The exclusion criteria included:

(a) patients with tumor invasion to major intrahepatic vasculature (portal vein and/or hepatic vein branches),

(b) patients with extrahepatic tumor metastasis, and

(c) patients with liver function status of Child-Pugh grade C.

For all patients in both groups, one dose of transarterial chemoembolization was given before SBRT or RFA. Antiviral medication (Entecavir 0.5mg daily po) was prescribed to all hepatitis B carriers in both groups.

2.1. Stereotactic body radiotherapy

SBRT system (Varian Company, America) was adopted for all patients in this group. A 4D – CT technology was also used to determine optimal treatment areas of target lesion. To enhance accuracy of tumor targeting, the breathing movement of patients was kept minimal (amplitude of liver movement was controlled within 5 mm). All patients received breathing exercise training to practice shallow breathing before the procedure. Two experienced intervention radiologists examined the gross tumor volume and the planning target volume of tumors. In selected cases, the irradiation field was adjusted by 50% to 60% of original prescription isodose curve surrounding planning target volume to avoid collateral organ damage. In general, the irradiation planning would be 5.5 to 10 Gy per day for 5 doses in 1 week. The total irradiation dose would be 27.5 to 50 Gy for each patient.

2.2. Radiofrequency ablation

All patients received RFA through percutaneous approach under ultrasound or CT guidance. The procedure adopt the Cool-tip radiofrequency system (Radionics, Burlington, MA). A single RF needle with an exposed length of 3 cm was used for tumor ≤ 3 cm in diameter, whereas a clustered needle (three parallel single needle close to each other) with an exposed length of 2.5 cm was used to treat large tumors > 3 cm. Patients were under monitored anesthetic control. Each RFA ablation cycle lasted for 8 to 12 min, and multiple overlapping ablation zones were required in large tumors. Upon completion of RFA procedure, needle track ablation was carried out to avoid tumor seeding along the needle track.

2.3. Data collection and outcome measures

Clinical data of all patients were collected in a database. The clinical details, short-term and long-term outcome measures were retrospectively evaluated in all 60 patients. The short-term outcome measures include post-procedure complication, treatment-related mortality, and complete remission (CR) rate at 3 months as measured by CT scan or MRI at 3 months after the procedure. A complication was defined as any adverse event after the procedure according to Clavien-Dindo classification.

Treatment-related mortality was defined as any death within 30 days after the procedure. All patients had monitoring of serum AFP level, chest radiograph, and CT scan/MRI every 3 to 4 months after the procedure. Local tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors formulized by the American Association for the Study of Liver Diseases. CR referred to the disappearance of the arterial contrast enhancement of all target lesions and this referred to complete local tumor control. Partial response referred to the reduction of the total diameter of the target lesion by ≥30% in the arterial contrast enhancement. Stable disease referred to the diameter of the lesion reduced by <30% or increased by <20%. Progressive disease referred to the increase in the diameter of the target lesion by ≥20%, or the appearance of a new lesion. Complete ablation rate of tumor referred to CR on imaging studies at 3 months after treatment. Local tumor control rate referred to CR, partial response, and stable disease on follow-up imaging studies.

2.4. Statistical analysis

Continuous data were expressed as median with ranges and were compared using Mann–Whitney U test. Categorical data were
compared using the Chi square test with Yates’ correction or the Fisher’s exact test where appropriate. The overall and disease-free survival rates were calculated by the Kaplan–Meier method and compared using the log-rank test. Hospital deaths were included in the overall survival analysis but were excluded from the disease-free survival analysis. All statistical analyses were performed using a statistical software (SPSS 25.0 for Windows, SPSS Inc., Chicago, IL). A P-value of less than .05 was considered statistically significant.

3. Results

3.1. Patient characteristics

Among 22 patients in SBRT group and 38 patients in RFA groups, there was no statistical significant difference in the baseline patient demographic characteristics, including age, gender, proportion of hepatic B carriers, presence of cirrhosis, comorbidity, and liver function in terms of liver biochemistry, Child-Pugh Grading, and Indocyanine Green – 15.

In terms of tumor characteristics, SBRT group has significantly larger tumor than RFA group, but the total tumor number was similar between two groups. Majority of patients in SBRT group had HCC at difficult anatomical locations (liver dome, n = 5; perivascular location, n = 15; subcapsular location, n = 3), whereas none of patients in RFA group had tumor at these difficult locations. The serum AFP level was also comparable between groups (Table 1).

3.2. Short-term outcome

There were nonspecific complaints from patients in both groups, including decreased appetite, nausea, and fatigue during first week after treatment. SBRT group had 5 patients (22.7%).

3.3. Long-term outcome

With median follow-up period of 26 months (range: 8–36 months), 2 patients in each group developed local tumor recurrence. The local tumor control rate was comparable between SBRT and RFA groups (90.9% vs. 94.7%). Ten of 22 patients (45.4%) in SBRT group and 20 of 38 patients (52.6%) in RFA group developed intrahepatic recurrence. There was no statistical significant difference between two groups (P = .592). Six patients (27.2%) in SBRT group but no patient in RFA group developed extrahepatic tumor metastasis. This might signify worse tumor biology in SBRT group than RFA group.

Table 1

| Characteristics                  | SBRT group (n = 22) | RFA group (n = 38) | P     |
|----------------------------------|--------------------|--------------------|-------|
| Age (years)                      | 66.5 (35.8–77)     | 61.5 (43.7–77)     | .243  |
| Gender (male: female)            | 16: 7              | 26: 7              | .237  |
| Hepatitis B infection            | 14 (63.6%)         | 26 (66.4%)         | .122  |
| Hepatitis C infection            | 0                  | 0                  | 1.000 |
| Presence of cirrhosis            | 12 (54.5%)         | 19 (50%)           | .734  |
| Comorbidity                      | 15 (68.2%)         | 31 (81.6%)         | .237  |
| Child-Pugh Grading               |                    |                    |       |
| Grade A: Grade B                 | 21: 1              | 35: 3              | .616  |
| Bilirubin (μmol/L)               | 10.6 (4.1–63.3)    | 16.8 (4.6–54.8)    | .263  |
| Albumin (g/L)                    | 38 (28.2–45.8)     | 38.8 (20.5–50.1)   | .788  |
| Serum AFP (mmol/L)               | 13.1 (2.3–27246)   | 5.9 (1.4–12508)    | .135  |
| Size of largest tumor (cm)       | 4.35 (0.8–9)       | 1.8 (1–4)          | <.001 |
| No. of tumors treated            |                    |                    |       |
| Single: multiple                 | 12: 10             | 18: 20             | .592  |
| Tumor at liver dome              | 5 (22.7%)          | 0                  | .002  |
| Perivascular tumor               | 15 (68.1%)         | 0                  | <.001 |
| Subcapsular tumor                | 3 (13.6%)          | 0                  | .019  |
| 30-day mortality                 | 0                  | 0                  | 1     |
| Hospital stay (days)             | 38 (4–14)          | 1.5 (1–9)          | .442  |
| Complete ablation rate           | 18 (81.8%)         | 34 (89.4%)         | .706  |

Continuous variable is expressed as median (range).
Categorical variable is expressed as number (percentage).
*AFP = Alpha fetoprotein level, RFA = radiofrequency ablation, SBRT = stereotactic body radiotherapy.

Table 2

| Characteristics                   | SBRT group (n = 22) | RFA group (n = 38) | P     |
|-----------------------------------|--------------------|--------------------|-------|
| Overall complications             | 5 (22.7%)          | 8 (21%)            | .879  |
| Fever                             | 5 (22.7%)          | 8 (21%)            | .879  |
| Liver failure                     | 0                  | 0                  | 1.000 |
| Biliary complication              | 0                  | 0                  | 1.000 |
| Intrahepatic vascular complication| 0                  | 0                  | 1.000 |
| Renal failure                     | 0                  | 0                  | 1.000 |
| Severe complications*             | 0                  | 0                  | 1.000 |
| Hospital mortality                | 0                  | 0                  | 1.000 |
| Complete ablation rate            | 18 (81.8%)         | 34 (89.4%)         | .400  |

Continuous variable is expressed as number (percentage).
Categorical variable is expressed as number (percentage).
*Severe postoperative complication according to Clavien-Dindo grade III or above.

Table 3

| Characteristics                   | SBRT group (n = 22) | RFA group (n = 38) | P     |
|-----------------------------------|--------------------|--------------------|-------|
| Local tumor control rate          | 20 (90.9%)         | 36 (94.7%)         | .566  |
| Intrahepatic recurrence           | 10 (45.4%)         | 20 (52.6%)         | .592  |
| Extrahepatic recurrence           | 6 (27.2%)          | 0                  | <.001 |
| Intrahepatic and extrahepatic recurrence | 1 (4.5%) | 1 (2.6%)          | .665  |
| Time to tumor recurrence (months) | 16 (2–33)          | 14 (1–33)          | .934  |
| Treatment of recurrence           |                    |                    |       |
| Local ablation (RFA)              | 3 (13.6%)          | 3 (7.9)            |       |
| TACE                               | 8 (36.3%)          | 1 (2.6)            |       |
| Systemic treatment                | 9 (40.9%)          | 0                  |       |
| Radiotherapy                      | 3 (13.6%)          | 0                  |       |
| Supportive care                   | 4 (18.1%)          | 0                  |       |

Continuous variable is expressed as median (range).
Categorical variable is expressed as number (percentage).
*AFP = Alpha fetoprotein level, RFA = radiofrequency ablation, SBRT = stereotactic body radiotherapy, TACE = transarterial chemoembolization.
time to tumor recurrence was similar between groups. Recurrent tumor were more likely treated by different therapies (local ablation, TACE, systemic therapy, and radiotherapy) in SBRT group than RFA group (Table 3). The 1-year and 2-year overall survival rate was 88.2% and 85.7% in SBRT group, and 100% and 75% in RFA group, respectively. There was no statistical significant difference between two groups ($P = .576$) (Fig. 1). Causes of death included liver failure in both groups, and hepatorenal syndrome and gastrointestinal bleeding in RFA group. The 1-year and 2-year tumor progression-free survival rate was comparable between SBRT group (50% and 13.6%) and RFA group (44.7% and 7.9%) ($P = .805$) (Fig. 2).

4. Discussion

The present study provides clinical evidence that SBRT can achieve similar oncological clearance rate as RFA for unresectable HCC and the short-term and long-term outcomes are similar between groups.

Currently, there are various modalities of local ablation therapy for HCC, including RFA, microwave ablation, cryotherapy with argon helium knife, and ethanol injection. Although RFA is recommended as a curative treatment modality for HCC in various international guidelines,[4,16–18] it is not without limitations. First, it involves direct puncture of liver tumor by RF needle, which might be difficult through percutaneous route in case of unfavorable tumor location at liver dome or in close proximity to surrounding organs. Second, “heat-sink” effect might reduce RFA efficacy when the ablation is carried out near major intrahepatic vasculature. Third, there is maximal size limitation (generally 5 cm) of tumor ablation by RFA.

The application of radiotherapy for liver tumor is limited in the past because the whole liver can only tolerate low doses of irradiation ($\sim 30$ Gy), which has limited therapeutic effect. With the advancement of tumor targeting techniques in radiotherapy, focal liver irradiation (SBRT) is possible and the dose can be up to $>70$ Gy, which is well tolerated by patients without major complication. It is less restricted by tumor location and liver function.[7] The mechanism of cytoreduction of SBRT is primarily related to direct tumor cell damage by ionizing radiation, which leads to breakdown of DNA strands, loss of clonogenicity, and subsequent cell death. SBRT makes use of hypofractionated high dose irradiation to minimize the possible repair of damaged DNA by tumor cells. The response of stroma surrounding tumors to irradiation, including tumor-associated small vessels and leukocyte populations, can also cause indirect effects on cancer cell death. In an early phase I clinical series, local tumor control rate was up to 100% with a 2-year overall survival of 60%. Sanuki et al[20] published another series on SBRT in 185 patients with HCC. The 3-year local tumor control rate was up to 91.6% in patients receiving 40 Gy irradiation. In the present study, the maximal irradiation dose was 50 Gy given in 2 weeks’ period and the local tumor control rate was 94.9%, which concurred with results from others.

One important finding of the present study is the comparable therapeutic effects (CR rate at 3 months [81.8% vs. 89.4%], local tumor control [90.9% vs. 94.7%], 2-year overall survival [85.7% vs. 75%] and 2-year tumor progression-free survival [13.6% vs. 7.9%]) between SBRT and RFA for unresectable HCC, although the tumor size in SBRT group is larger than that of RFA group. The comparison of therapeutic efficacy between SBRT and RFA has been studied in other studies. Kim et al[10] performed a recent
propensity matching analysis comparing SBRT (n = 313) with RFA (n = 313). With a median follow-up of 27.7 months, 3-year local tumor recurrence rate was significantly lower in SBRT group (21.2%) than RFA group (27.9%). SBRT was superior to RFA in terms of tumor control rate in large tumor in subphrenic region and those tumor progressed after transarterial chemotherapy. Another more recent comparative study by Jeong et al[11] revealed that the 4-year local tumor control rate (96.3% vs. 90.6%) and overall survival rate (70.2% vs. 71.8%) were similar between SBRT and RFA after matching. The severe complication rate was also similar between two groups (1.1% vs. 0.6%). Subsequently, Lee et al[21] published a systemic review and meta-analysis on 11 studies involving 2238 patients. There was no significant difference in pooled 2-year local tumor control between SBRT group (84.5%) and RFA group (79.5%). More recently, another meta-analysis by Eriguchi et al[13] has shown that SBRT was associated with similar overall survival but better local tumor control (HR 0.39) comparing to RFA when Barcelona Liver Cancer Staging factors were matched between groups. Up till now, there is only one randomized controlled trial comparing proton beam radiotherapy with RFA for recurrent HCC by Kim et al.[22] The results showed that proton beam radiotherapy resulted in better 2-year local progression-free survival than RFA (92.8% vs. 83.2%). Judging from all these study results, the tumor control rate of SBRT is at least comparable, if not better, to RFA.

Irradiation-induced liver toxicity is of great concern in conventional radiotherapy to liver. It can manifest as deranged liver function, hepatomegaly, and acute cholangitis. Occasionally, there may be bystander effect of irradiation causing hepatitis B viral reactivation and liver derangement.[23] One major merit of SBRT is its hypofractionated nature which can minimize long irradiation course that might lead to cytokine-induced liver toxicity. In the present study, there is no incidence of irradiation-induced liver toxicity nor major complication event in SBRT group.

Another aspect of SBRT relates to its nature of tumor microenvironment modulation and immune-modulation depending on the dosage of irradiation. These include T-cell activation and tumor-antigen presentation changes.[24] These immune responses form the basis of combination therapy in which SBRT is combined with newly developed immunotherapeutic drugs in management of HCC. Besides, abscopal effect associated with SBRT has been studied recently. It involves shrinkage of tumors outside the scope of the localized treatment of tumor by SBRT. The possible underlying mechanism relates to the possible activation of immune system by ionizing irradiation against tumor cells.[25]

The present study is limited by the small patient number in both SBRT and RFA groups and its retrospective in nature. There is heterogeneity of tumor characteristics between two groups. Nonetheless, it provides some clinical insights regarding clinical efficacy of SBRT for HCC and it may form the basis of designing prospective study comparing SBRT with other locoregional therapy for HCC.

To conclude, this retrospective study has shown the comparable short-term and long-term outcomes between SBRT and RFA for unresectable HCC. Future prospective clinical study is needed to justify its role in patients with HCC.
**Author contributions**

Conceptualization: Ren Ji, Kelvin K. Ng.
Data curation: Ren Ji, G. Wu.
Formal analysis: Ren Ji.
Investigation: Ren Ji, Wenqi Chen, Weihong Yang, Hongtao Zhu, Chi-Leung Chiang, Tiffany C.L. Wong, Feng-Ming Kong.
Methodology: Ren Ji, Kelvin K. Ng, Wenqi Chen.
Project administration: Tan-To Cheung, Chung-Mau Lo.
Supervision: Chung-Mau Lo.
Writing – original draft: Ren Ji.
Writing – review & editing: Kelvin K. Ng, G. Wu.

**References**

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.

[2] Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001;91:1479–86.

[3] Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011;253:745–58.

[4] European Association for the Study of the Liver . EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69:182–236.

[5] Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg 2008;12:183–91.

[6] Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216–22.

[7] Meyer J, Singal AG. Stereotactic ablative radiotherapy for hepatocellular carcinoma: history, current status, and opportunities. Liver Transplant 2018;24:420–7.

[8] Huertas A, Baumann AS, Saunier-Kubs F, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol 2015;115:211–6.

[9] Wahl DR, Stemmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016;34:452–9.

[10] Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol 2020;73:121–9.

[11] Jeong Y, Lee KJ, Lee SJ, et al. Radiofrequency ablation versus stereotactic body radiation therapy for small (≤3 cm) hepatocellular carcinoma: a retrospective comparison analysis. J Gastroenterol Hepatol 2021; 36:1962–70.

[12] Pan YX, Fu YZ, Hu DD, et al. Stereotactic body radiotherapy vs. radiofrequency ablation in the treatment of hepatocellular carcinoma: a meta-analysis. Front Oncol 2020;10:1639.

[13] Eriguchi T, Takeda A, Tateishi Y, et al. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: systematic review and meta-analysis of propensity score studies. Hepatol Res 2021;51:813–22.

[14] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 1836 patients and results of a survey. Ann Surg 2004;240:205–13.

[15] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.

[16] Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29 Suppl 4:v1238–55.

[17] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317–70.

[18] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358–80.

[19] Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. J Radiat Oncol 2010;12:218–25.

[20] Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014;53:399–404.

[21] Lee J, Shin B, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radioter Oncol 2020;145:63–70.

[22] Kim TH, Koh YH, Kim BH, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol 2021;74:603–12.

[23] Chou CH, Chen PJ, Lee PH, Cheng AL, Hsu HC, Cheng JC. Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells. Clin Cancer Res 2007;13:851–7.

[24] Demaria S, Guha C, Schoenfeld J, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer 2021;9.

[25] Reynaerts K, Illidge T, Siva S, Chang YJ, De Ruyscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015; 41:503–10.